Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 8/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 7/20 | 0.51 |
| ▸ | TUBB | P07437 | 7/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 7/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 7/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 7/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 7/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 0.51 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 7/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413621 | 0.85 | TUBB3 (0.55) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL251127 | 0.80 | PIK3CA (0.44) | KDREGFRPDGFRB | |
| SCHEMBL3646114 | 0.77 | MEN1 (0.42) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL14296926 | 0.76 | ADORA3 (0.47) | — | |
| SCHEMBL6747378 | 0.76 | XDH (0.37) | — | |
| SCHEMBL3000771 | 0.74 | MAPT (0.52) | — | |
| SCHEMBL4232868 | 0.72 | EGFR (0.50) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL3108534 | 0.71 | CCNE2 (0.61) | EGFR | |
| SCHEMBL3108529 | 0.71 | MAPT (0.37) | — | |
| SCHEMBL19313054 | 0.70 | KDR (0.54) | KDREGFRPDGFRBTUBB3TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | KDR 3722/4885EGFR 3147/4885PDGFRB 2783/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.